Intabio provides an analytical platform to transform and accelerate the development of biotherapeutic drugs by enabling early product quality characterization and producing profound efficiency gains across all stages of biopharmaceutical development and manufacturing.

 

The development and manufacturing of biologics requires high levels of monitoring and testing due to the fact that antibody and recombinant protein drugs are produced in living cells that often introduce unintended structural modifications that can affect efficacy and toxicity. Current testing systems are cumbersome and do not provide the throughput and real-time protein analytics that today’s rapidly growing biopharma industry desperately needs.  Intabio was founded to address this critical issue in protein analytics and our solution is based on a decade’s worth of deep customer insights and needs.  We are developing the BlazeTM system to address the acute pain in biologics product development and manufacturing. Our first product will provide rapid and direct identification of the subtle protein modifications - modifications that can undermine the stability and efficacy of biotherapeutic drugs such as monoclonal antibodies and recombinant proteins. Intabio’s proprietary microfluidics-based technology provides an easy to use, robust and rapid, analytical platform to separate, quantitate, and seamlessly transfer separated proteins by electrospray to an adjacent mass spectrometer for molecular identification.

 

The Blaze system is comprised of a bench-top instrument, microfluidic chip and reagent kit and provides (1) separation of intact protein isoforms by charge heterogeneity analysis (cIEF), (2) imaging at 280nm for quantitation of each protein isoform, and (3) sample preparation and electrospray delivery into an adjacent mass spectrometer in order to identify the unknown modifications. The Blaze system also has the flexibility to run as a stand-alone instrument for imaged cIEF analysis.

 

Intabio’s breakthrough Blaze system uniquely integrates the analytical techniques of separation, quantitation, and molecular mass determination into a seamless process. Because the Blaze instrument provides an analysis in only minutes as compared with the days or weeks required  with current technologies, biopharmaceutical scientists will be able to characterize protein drug quality in real-time and on hundreds more samples than is currently possible. By enabling the interrogation of product quality much earlier in the development process, the Blaze system provides invaluable insights for key development decisions and can reduce the risk of downstream bioproduction issues.

 

Contact Us

 

Follow us on LinkedIn

 

 

Management

 

Lena Wu, Ph.D. CEO & President, Co-founder. Lena is responsible for the company’s financing, corporate and business development strategy and execution. She was previously the CEO, President and co-founder of Rogne Biosciences, a therapeutic dermatology company. Lena has extensive management experience in companies developing and commercializing microfluidic-based products. She was the Vice-President of Corporate Development of On-Q-ity, a microfluidic-based, cancer diagnostic device company, and was also the Director of Business Development at Caliper Technologies, a microfluidic platform company developing analytical instrumentation systems for life science and diagnostic markets. Lena has 20 years of industry experience, and has advanced the strategic objectives as an operational business consultant for emerging companies across therapeutic, diagnostic and life science sectors.  She began her business career at Millennium Pharmaceuticals, following a post-doc in yeast genetics at Harvard.

 

Erik Gentalen, CTO, Co-founder, Inventor. Erik is the inventor of Intabio’s microfluidic-based innovations, and is responsible for advancing the technology and the overall development of the BlazeTM system. Erik has spent over 16 years developing microfluidic tools for the analysis of proteins and nucleic acids. Prior to Intabio, Erik was the Director of Systems Integration at ProteinSimple where he led the R&D team developing the Simple Western capillary immunoassay from invention to launch, and also led product support for the iCE3 capillary-based IEF system. Prior to ProteinSimple, he was the Program Manager at Caliper Life Sciences, where he led the system integration for a microfluidic research system, developed chip designs for customer applications, and managed application development collaborations with pharmaceutical partners. Erik was also an early employee at Affymetrix and Combimatrix, where his responsibilities included designing instrumentation, developing synthesis methods, managing the DNA array production facility, and collaborating on novel array applications. Erik is also a registered patent agent.

 

 

Board

 

Erik Gentalen, CTO, Co-founder, Inventor

 

Jenny Rooke, Ph.D., Board Director. Jenny is the Managing Director at 5 Prime Ventures, where she invests in early stage life sciences companies specializing in research tools, diagnostics, and synthetic biology. Jenny’s investing experience includes roles at F-Prime Capital, where she served as a Kauffman Fellow, Anterra Capital, and with the Bill & Melinda Gates Foundation. Prior to investing, she held multiple executive positions at U.S. Genomics, a life venture-backed science tools start-up focused on advancing single molecule detection technologies. While there, Jenny was responsible for the development and launch of the company’s first product line, assays for microRNA detection. She also led internal science and marketing teams in analyses of potential applications/markets for the company’s technologies and co-invented a novel genetic testing method that was licensed to Quest Diagnostics, generating a revenue stream. Dr. Rooke holds a PhD in genetics from Yale University and a BS in Physics from Georgia Tech.

 

Lena Wu, Ph.D., CEO & President, Co-founder

 

 

 Technical Advisors

 

Lou Dietz, M.S. Lou has extensive experience in imaging systems, optical detection, and microfluidics for life science applications, and has developed numerous successful products for the medical diagnostic and bioanalytical research markets. He is currently the Vice-President of Engineering at Biodesy. As a consultant, he has designed FDA-cleared products for digital pathology and point-of-care diagnostic testing. He has also held senior engineering management roles in several companies, such as On-Q-ity (formerly CELLective DX), Nanoplex Technologies, and SurroMed, where he has managed teams developing microfluidic devices and instrumentation for analyzing circulating tumor cells in blood samples, automated manufacturing of microparticles and nanoparticles for multiplexed immunoassays, and automated laser-scanning cytometry systems for biomarker discovery and clinical diagnostics. The author or co-author of federal grants totaling $13 million, he holds 15 U.S. patents covering optical instrumentation, nanoparticle manufacturing techniques, and electronic circuitry for communications systems. He received his B.S. and M.S. in Electrical Engineering from Stanford University.

 

Khushroo Gandhi, Ph.D. Khushroo has extensive experience in product development and microfluidics device fabrication in various substrates such as silicon, glass and polymers.  He is currently the Vice-President of Product Development and Manufacturing at GBP Scientific, where he is leading the product development and manufacturing activities for both instrument and consumables. Previously, he was at Caliper, (a Perkin Elmer company) where he held multiple leadership roles, including Site Manager and Director of Process Development and Engineering. He was responsible for all operations of microfluidic consumables manufacturing site with over $20M in annual revenue, led large multi-disciplinary projects such as improving the Quality Management system, obtaining ISO13485 registration, transferring manufacturing technology among sites, and directed scale-up efforts and manufacturing of various microfluidic chip and reagent product lines.

 

Bill Hyun, M.S., Ph.D. Bill is the Director of the Laboratory for Advanced Cytometry at the University of California, San Francisco (UCSF). He leverages over 25 years of translational and clinical research experience into founder, investor and advisor roles for several biotechnology companies and life science investment groups. At UCSF, he helped build the world’s largest academic cytometry facility and continues to design and build next generation cell sorters, commercial flow cytometers and confocal microscopes.

 

Anne Kopf-Sill, Ph.D. Anne has been working in product development in the life science tools and medical diagnostic space for 30 years. She is the inventor or co-inventor on more than 50 patents in the areas of microfluidics and diagnostics. Her expertise is in product development and marketing for new technologies in life science and diagnostic markets. Most of the products that she has developed are multidisciplinary, involving the development of a consumable, reagents, instrument, and software. Anne currently has a position at the Stanford Office of Technology Transfer, where she evaluates Stanford professors’ and grad students’ inventions for commercial potential, gets patents drafted, finds companies to license the technology and executes the licenses. Prior to this position, she was at Tecan Systems overseeing the R&D for a new microfluidic platform using electrowetting. Previous positions included being President of CellPoint Diagnostics developing technology for detecting and analyzing circulating tumor cells in cancer patients. Before that she was Sr. VP of Product Development & Operations at NuGEN making reagent kits to amplify and study nucleic acids. She was one of the first employees at Caliper Technologies and built and ran their microfluidics group for many years. Early in her career, she developed and marketed a point-of-care diagnostic product to analyze blood chemistries from a single drop of blood while at Abaxis and developed research instruments at Molecular Devices.

 

 

News

 

Intabio Announces $2M Seed Financing

 

 

 

Contact Us

Submitting Form...

The server encountered an error.

Form received.